Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus.
Pneumocystis
adults
cancer
children
clinical trials
consensus
definitions
transplantation
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
12 03 2021
12 03 2021
Historique:
entrez:
12
3
2021
pubmed:
13
3
2021
medline:
28
4
2021
Statut:
ppublish
Résumé
Pneumocystis jirovecii pneumonia (PCP) causes substantive morbidity in immunocompromised patients. The EORTC/MSGERC convened an expert group to elaborate consensus definitions for Pneumocystis disease for the purpose of interventional clinical trials and epidemiological studies and evaluation of diagnostic tests. Definitions were based on the triad of host factors, clinical-radiologic features, and mycologic tests with categorization into probable and proven Pneumocystis disease, and to be applicable to immunocompromised adults and children without human immunodeficiency virus (HIV). Definitions were formulated and their criteria debated and adjusted after public consultation. The definitions were published within the 2019 update of the EORTC/MSGERC Consensus Definitions of Invasive Fungal Disease. Here we detail the scientific rationale behind the disease definitions. The diagnosis of proven PCP is based on clinical and radiologic criteria plus demonstration of P. jirovecii by microscopy using conventional or immunofluorescence staining in tissue or respiratory tract specimens. Probable PCP is defined by the presence of appropriate host factors and clinical-radiologic criteria, plus amplification of P. jirovecii DNA by quantitative real-time polymerase chain reaction (PCR) in respiratory specimens and/or detection of β-d-glucan in serum provided that another invasive fungal disease and a false-positive result can be ruled out. Extrapulmonary Pneumocystis disease requires demonstration of the organism in affected tissue by microscopy and, preferably, PCR. These updated definitions of Pneumocystis diseases should prove applicable in clinical, diagnostic, and epidemiologic research in a broad range of immunocompromised patients without HIV.
Sections du résumé
BACKGROUND
Pneumocystis jirovecii pneumonia (PCP) causes substantive morbidity in immunocompromised patients. The EORTC/MSGERC convened an expert group to elaborate consensus definitions for Pneumocystis disease for the purpose of interventional clinical trials and epidemiological studies and evaluation of diagnostic tests.
METHODS
Definitions were based on the triad of host factors, clinical-radiologic features, and mycologic tests with categorization into probable and proven Pneumocystis disease, and to be applicable to immunocompromised adults and children without human immunodeficiency virus (HIV). Definitions were formulated and their criteria debated and adjusted after public consultation. The definitions were published within the 2019 update of the EORTC/MSGERC Consensus Definitions of Invasive Fungal Disease. Here we detail the scientific rationale behind the disease definitions.
RESULTS
The diagnosis of proven PCP is based on clinical and radiologic criteria plus demonstration of P. jirovecii by microscopy using conventional or immunofluorescence staining in tissue or respiratory tract specimens. Probable PCP is defined by the presence of appropriate host factors and clinical-radiologic criteria, plus amplification of P. jirovecii DNA by quantitative real-time polymerase chain reaction (PCR) in respiratory specimens and/or detection of β-d-glucan in serum provided that another invasive fungal disease and a false-positive result can be ruled out. Extrapulmonary Pneumocystis disease requires demonstration of the organism in affected tissue by microscopy and, preferably, PCR.
CONCLUSIONS
These updated definitions of Pneumocystis diseases should prove applicable in clinical, diagnostic, and epidemiologic research in a broad range of immunocompromised patients without HIV.
Identifiants
pubmed: 33709126
pii: 6168269
doi: 10.1093/cid/ciaa1805
pmc: PMC8243279
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S114-S120Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Eur J Radiol. 2012 Jun;81(6):1315-20
pubmed: 21420818
J Clin Microbiol. 2014 Sep;52(9):3370-6
pubmed: 25009050
Clin Infect Dis. 2010 Apr 15;50(8):1091-100
pubmed: 20218877
Eur J Radiol. 2019 Jul;116:116-127
pubmed: 31153552
J Med Microbiol. 2020 May;69(5):705-711
pubmed: 32369002
Cold Spring Harb Perspect Med. 2014 Nov 03;4(12):a019828
pubmed: 25367973
Emerg Infect Dis. 2011 Oct;17(10):1855-64
pubmed: 22000355
J Clin Microbiol. 2013 Oct;51(10):3380-8
pubmed: 23903553
Emerg Infect Dis. 2014 Sep;20(9):1490-7
pubmed: 25148074
Expert Rev Anti Infect Ther. 2019 Oct;17(10):787-801
pubmed: 31550942
Expert Rev Anti Infect Ther. 2010 Jun;8(6):683-701
pubmed: 20521896
Pediatrics. 1978 Jan;61(1):35-41
pubmed: 400818
J Clin Microbiol. 2019 May 24;57(6):
pubmed: 30918045
Transpl Infect Dis. 2014 Apr;16(2):213-24
pubmed: 24589027
Clin Microbiol Rev. 1997 Jul;10(3):401-18
pubmed: 9227859
Clin Infect Dis. 2004 Dec 1;39(11):1563-71
pubmed: 15578352
Cancer. 1975 Dec;36(6):2004-9
pubmed: 1081905
J Infect Chemother. 2019 Dec;25(12):936-942
pubmed: 31186197
Am J Med. 1993 Feb;94(2):216-9
pubmed: 8381584
Am Rev Respir Dis. 1979 Dec;120(6):1283-7
pubmed: 391111
Chest. 2013 Jul;144(1):258-265
pubmed: 23258406
Am J Hematol. 1995 Jun;49(2):135-42
pubmed: 7771465
Ann Intern Med. 1984 May;100(5):663-71
pubmed: 6231873
Semin Respir Infect. 1998 Dec;13(4):283-8
pubmed: 9872624
N Engl J Med. 1977 Dec 29;297(26):1419-26
pubmed: 412099
Semin Respir Infect. 1998 Dec;13(4):330-8
pubmed: 9872630
J Antimicrob Chemother. 2016 Sep;71(9):2386-96
pubmed: 27550991
Br J Haematol. 2002 May;117(2):379-86
pubmed: 11972521
Clin Infect Dis. 1998 Apr;26(4):1005-6
pubmed: 9564499
Clin Infect Dis. 2001 Mar 15;32(6):855-61
pubmed: 11247708
Rev Chilena Infectol. 2014 Aug;31(4):417-24
pubmed: 25327195
J Fungi (Basel). 2019 Dec 26;6(1):
pubmed: 31888050
N Engl J Med. 2002 Aug 8;347(6):408-15
pubmed: 12167683
Clin Microbiol Rev. 2012 Apr;25(2):297-317
pubmed: 22491773
Blood. 2000 Jul 15;96(2):754-62
pubmed: 10887145
J Infect Chemother. 2014 Nov;20(11):678-81
pubmed: 25066434
Clin Infect Dis. 2002 Jan 1;34(1):7-14
pubmed: 11731939
Respiration. 2018;96(1):52-65
pubmed: 29635251
Intern Med. 2010;49(4):273-81
pubmed: 20154431
Emerg Infect Dis. 2013 Oct;19(10):1612-9
pubmed: 24048016
Ann Intern Med. 1986 Mar;104(3):338-44
pubmed: 3511821
Respir Res. 2013 Aug 28;14:87
pubmed: 23981859
Crit Rev Microbiol. 2010 Nov;36(4):271-81
pubmed: 20854193
Med Mycol. 2020 Aug 1;58(6):779-788
pubmed: 31758173
Clin Infect Dis. 2017 Jun 1;64(11):1557-1563
pubmed: 28472247
Clin Microbiol Infect. 2020 Sep;26(9):1137-1143
pubmed: 32479781
Clin Infect Dis. 2010 Apr 15;50(8):1101-11
pubmed: 20218876
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Clin Infect Dis. 1993 Nov;17 Suppl 2:S416-22
pubmed: 8274607
Scand J Infect Dis. 1997;29(6):591-3
pubmed: 9571740
Am J Med. 2014 Dec;127(12):1242.e11-7
pubmed: 25058862
Klin Padiatr. 2001 Sep;213 Suppl 1:A38-49
pubmed: 11577363
Natl Cancer Inst Monogr. 1976 Oct;43:41-7
pubmed: 1087959
Clin Infect Dis. 2012 Mar 1;54(5):633-43
pubmed: 22198786
Clin Infect Dis. 2015 Mar 1;60(5):713-20
pubmed: 25414266
Pulmonology. 2019 Sep - Oct;25(5):271-274
pubmed: 31076291
Clin Infect Dis. 2019 Sep 27;69(8):1303-1309
pubmed: 30561560
Thorax. 2003 Jul;58(7):594-7
pubmed: 12832674
Lung. 2010 Apr;188(2):159-63
pubmed: 20049469
Med Mal Infect. 2011 Oct;41(10):526-31
pubmed: 21864998
Am Rev Respir Dis. 1989 Nov;140(5):1204-9
pubmed: 2817582
Crit Care. 2008;12(1):R28
pubmed: 18304356
Diagn Interv Imaging. 2012 Jun;93(6):431-40
pubmed: 22658280
Clin Infect Dis. 2007 May 15;44(10):1289-97
pubmed: 17443465
PLoS One. 2014 Jul 16;9(7):e101943
pubmed: 25029342
J Infect Chemother. 2014 Jul;20(7):412-6
pubmed: 24767467
Ann Intern Med. 1989 Aug 1;111(3):223-31
pubmed: 2546472
Transpl Infect Dis. 2012 Oct;14(5):510-8
pubmed: 22548840
Pediatr Pol. 1983 Apr;58(4):337-40
pubmed: 6605512
Clin Infect Dis. 2008 Jun 15;46(12):1864-70
pubmed: 18462174
Am Rev Respir Dis. 1988 Jun;137(6):1268-74
pubmed: 3144196
J Clin Invest. 1997 May 1;99(9):2110-7
pubmed: 9151783
J Crit Care. 2014 Jun;29(3):356-61
pubmed: 24440053
Clin Microbiol Infect. 2011 Oct;17(10):1531-7
pubmed: 20946413
N Engl J Med. 1988 Mar 10;318(10):589-93
pubmed: 2449613
Transpl Infect Dis. 2017 Apr;19(2):
pubmed: 28035717
Lancet. 2016 Feb 20;387(10020):760-9
pubmed: 26684607
N Engl J Med. 2004 Jun 10;350(24):2487-98
pubmed: 15190141
Mycoses. 2019 Nov;62(11):1015-1022
pubmed: 31494981
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
J Clin Microbiol. 2012 Jan;50(1):7-15
pubmed: 22075593
Pathology. 1994 Jul;26(3):325-8
pubmed: 7527514
J Antimicrob Chemother. 2009 Dec;64(6):1282-90
pubmed: 19858161
J Microbiol Immunol Infect. 2014 Feb;47(1):42-7
pubmed: 23063081